EUVIMEDEUVIMED entdecken
Crossref

Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients

Tatsuzo Mishina iD, Chikako Ohwada, Tomoki Suichi, Shinichiro Matsui, Arata Ishii, Koji Takaishi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto iD, Yusuke Takeda, Sonoko Misawa, Naoya Mimura, Satoshi Kuwabara und 2 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Tatsuzo Mishina und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Chiba University Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: POEMS Syndrome, Osteolysis. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features. Clinical data and bone lesion information by computed tomography (CT) imaging were obtained from the 114 patients with POEMS syndrome. Regardless of the presence of sclerotic bone lesions, patients were divided into two groups according to the presence (lytic group: n = 17, 14.9%) or absence (non‐lytic group: n = 97, 85.1%) of osteolytic lesions. In the lytic group, several patients were histologically diagnosed with plasmacytoma. In the evaluation by CT imaging, osteolytic lesions had a higher response rate than sclerotic lesions (75.0% vs. 42.2%, p = 0.079). Nevertheless, patients in lytic group showed earlier clinical progression than patients in non‐lytic group (2‐year progression‐free survival, 66.7% vs. 90.2%, p = 0.069). The presence of innumerable bone lesions was an independent poor prognostic factor in multivariate analysis, regardless of the presence of osteolytic lesions (hazard ratio, 3.4; 95% confidence interval 1.1–10.9; p = 0.040). Osteolytic and innumerable bone lesions are potential prognostic factors. Further studies involving histopathological evaluations of bone lesions are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

POEMS SyndromeOsteolysisHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultPrognosisTomography, X-Ray Computed

Stichwörter der Autor:innen

POEMS syndromebone lesioncomputed tomographyosteolysisosteosclerosis

Autor:innen und Institutionen

  • Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Division of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
  • Department of Hematology, International University of Health and Welfare, Narita, Japan.
  • Department of Neurology, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.

ORCID-Profile: Tatsuzo Mishina, Shokichi Tsukamoto, Chiaki Nakaseko

Zitieren

APA

Mishina, T., Ohwada, C., Suichi, T., Matsui, S., Ishii, A., Takaishi, K., Oshima-Hasegawa, N., Tsukamoto, S., Takeda, Y., Misawa, S., Mimura, N., Kuwabara, S., Nakaseko, C., & Sakaida, E. (2025). Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients. Hematological Oncology. https://doi.org/10.1002/hon.70037

Vancouver

Mishina T, Ohwada C, Suichi T, Matsui S, Ishii A, Takaishi K, et al. Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients. Hematological Oncology. 2025. doi:10.1002/hon.70037

BibTeX
@article{Mishina2025,
  author = {Mishina, Tatsuzo and Ohwada, Chikako and Suichi, Tomoki and Matsui, Shinichiro and Ishii, Arata and Takaishi, Koji and Oshima-Hasegawa, Nagisa and Tsukamoto, Shokichi and Takeda, Yusuke and Misawa, Sonoko and Mimura, Naoya and Kuwabara, Satoshi and Nakaseko, Chiaki and Sakaida, Emiko},
  title = {Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single‐Center Experience of 114 Patients},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70037}
}
Kostenlos starten →